September 14, 2025 a 07:43 pm
LLY: Fundamental Ratio Analysis - Eli Lilly and Company
Eli Lilly and Company, a leader in the pharmaceuticals industry, is recognized for its innovative drug solutions. Despite challenges in the competitive healthcare sector, Eli Lilly exhibits a solid financial standing, making its stock an interesting prospect for investors.
Fundamental Rating
The fundamental metrics of Eli Lilly indicate a moderately strong position with areas requiring attention.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
Analysis over time shows consistent performance with minor fluctuations.
| Date | Overall Score | Discounted Cash Flow | Return on Equity | Return on Assets | Debt to Equity | Price to Earnings | Price to Book |
|---|---|---|---|---|---|---|---|
| 2025-09-12 | 3 | 4 | 5 | 5 | 1 | 1 | 1 |
| N/A | 0 | 4 | 5 | 5 | 1 | 1 | 1 |
Analyst Price Targets
Price targets present a bullish outlook, despite some divergence in predictions.
| High | Low | Median | Consensus |
|---|---|---|---|
| 1050 | 700 | 715 | 798 |
Analyst Sentiment
The sentiment is predominantly positive, favoring a 'Buy' recommendation.
| Recommendation | Count | Visual |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 32 | |
| Hold | 8 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Eli Lilly and Company shows a stable financial foundation and positive analyst sentiment, supported by its innovative pharmaceutical portfolio. However, the company's rating for debt to equity and valuation metrics suggests potential financial risks. With a strong market position and optimistic price targets, the stock provides compelling opportunities for investors seeking exposure in the healthcare sector.